semaglutide cardiovascular outcomes trial and in Obesity without Diabetes SELECT Cardiovascular Trial Information |

The frustration of medication effects plateauing applies to sexual side effects too, where the initial disruption typically moderates over time as both partners adapt

Pediatr Neurol (2013) 49(4):2326

Risk of Thyroid C-Cell Tumours: In studies with rodents, semaglutide caused thyroid C-cell tumours

For patients where surgery is medically appropriate, the results are in a completely different category than anything a dietary supplement can offer

As patients progress through dose escalationadvancing by 0.25mg or 0.5mg increments every 4 weeksthe pen's duration per patient shortens

If approved, it would represent a significant milestone, becoming the first oral GLP-1 treatment specifically for obesity with an efficacy profile on par with the most potent injectables